Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma

被引：420

作者：

Keating, Gillian M. ^{[1
,2
]}

Santoro, Armando ^{[3
]}

机构：

[1] Wolters Kluwer Hlth Adis, Auckland, New Zealand

[2] Wolters Kluwer Hlth, Conshohocken, PA USA

[3] Ist Clin Humanitas, Dept Med Oncol & Hematol, Milan, Italy

来源：

DRUGS | 2009年 / 69卷 / 02期

关键词：

PHASE-I; RAF/MEK/ERK PATHWAY; BAY-43-9006; COMBINATION; THERAPY; CANCER; MODEL; RISK;

D O I：

10.2165/00003495-200969020-00006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sorafenib (Nexavar (R)) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization. Sorafenib is generally well tolerated in patients with advanced hepatocellular carcinoma. Thus, sorafenib represents an important advance in the treatment of advanced hepatocellular carcinoma and is the new standard of care for this condition.

引用

页码：223 / 240

页数：18